Summary by Futu AI
Innovent bio pharmaceutical announced that its newly developed drug, Marcytepa (IBI362), a GLP-1R/GCGR dual agonist for the treatment of type 2 diabetes, has officially received new drug application acceptance (NDA) from China's National Medical Products Administration (NMPA). The application is based on the results of two Phase III clinical studies that demonstrate Marcytepa's superior effects in blood glucose control and weight loss, and can improve cardiovascular, hepatic, and renal indicators without finding new safety risks. Marcytepa is the first GLP-1R/GCGR dual agonist for T2D Phase III clinical trials in China and is expected to provide more effective disease management for more than 0.14 billion diabetic patients in China. Innovent bio will closely collaborate with regulatory agencies and expects to launch this drug to the market soon.